Literature DB >> 9659587

Lipoxygenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth.

T W Moody1, J Leyton, A Martinez, S Hong, A Malkinson, J L Mulshine.   

Abstract

The effects of lipoxygenase inhibitors were investigated using human lung cancer cell lines and A/J mice. By RT-PCR, 5-, 12-, and 15-lipoxygenase mRNA was detected in NSCLC cells. NDGA inhibited 5-LO activity in adenocarcinoma cell line NCI-H1264. Using an MTT assay, NDGA, MK591 and AA861 inhibited the growth of NSCLC cell lines tested with IC50 values of 3, 2, and 7 microM, respectively. Using a clonogenic assay, 10 microM NDGA significantly reduced NSCLC colony number. NDGA significantly slowed NSCLC xenograft growth in nude mice. When the tumors were excised and analyzed, nude mice treated with NDGA had significantly more apoptotic figures than did untreated tumors. A/J mice treated with urethane developed adenomas after 4 months and NDGA administration significantly reduced lung adenoma number. These data indicate that lipoxygenase inhibitors inhibit lung cancer growth and prevent lung carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9659587     DOI: 10.3109/01902149809087390

Source DB:  PubMed          Journal:  Exp Lung Res        ISSN: 0190-2148            Impact factor:   2.459


  20 in total

Review 1.  Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update.

Authors:  Jian-Ming Lü; Jacobo Nurko; Sarah M Weakley; Jun Jiang; Panagiotis Kougias; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  Med Sci Monit       Date:  2010-05

2.  Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia.

Authors:  Vemparala Subbarayan; Xiao-Chun Xu; Jeri Kim; Peiying Yang; Ashraful Hoque; Anita L Sabichi; Norma Llansa; Gabriella Mendoza; Christopher J Logothetis; Robert A Newman; Scott M Lippman; David G Menter
Journal:  Neoplasia       Date:  2005-03       Impact factor: 5.715

Review 3.  Biosynthesis, biological effects, and receptors of hydroxyeicosatetraenoic acids (HETEs) and oxoeicosatetraenoic acids (oxo-ETEs) derived from arachidonic acid.

Authors:  William S Powell; Joshua Rokach
Journal:  Biochim Biophys Acta       Date:  2014-10-29

Review 4.  Role of 15-lipoxygenase/15-hydroxyeicosatetraenoic acid in hypoxia-induced pulmonary hypertension.

Authors:  Daling Zhu; Yajuan Ran
Journal:  J Physiol Sci       Date:  2012-02-14       Impact factor: 2.781

Review 5.  Molecular targets of phytochemicals for cancer prevention.

Authors:  Ki Won Lee; Ann M Bode; Zigang Dong
Journal:  Nat Rev Cancer       Date:  2011-02-10       Impact factor: 60.716

6.  Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene.

Authors:  U P Kelavkar; K F Badr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-13       Impact factor: 11.205

7.  Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.

Authors:  Gary E Meyer; Louis Chesler; Dandan Liu; Karissa Gable; Betty A Maddux; David D Goldenberg; Jack F Youngren; Ira D Goldfine; William A Weiss; Katherine K Matthay; Stephen M Rosenthal
Journal:  J Cell Biochem       Date:  2007-12-15       Impact factor: 4.429

8.  Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid.

Authors:  Ross O Meyers; Joshua D Lambert; Nicole Hajicek; Alan Pourpak; John A Kalaitzis; Robert T Dorr
Journal:  Bioorg Med Chem Lett       Date:  2009-06-21       Impact factor: 2.823

Review 9.  5-Oxo-ETE and the OXE receptor.

Authors:  Gail E Grant; Joshua Rokach; William S Powell
Journal:  Prostaglandins Other Lipid Mediat       Date:  2009-05-18       Impact factor: 3.072

10.  Naturally occurring lignans efficiently induce apoptosis in colorectal tumor cells.

Authors:  B Hausott; H Greger; B Marian
Journal:  J Cancer Res Clin Oncol       Date:  2003-07-31       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.